(3R)-3-ethoxypiperidine | 956429-50-8

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 哌啶类
• 英文名称: (3R)-3-ethoxypiperidine
• CAS: 956429-50-8
• 化学式: C₇H₁₅NO
• 分子量: 129.2
• InChiKey: RYNGVDXHFTWXDH-SSDOTTSWSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  0.6
• 重原子数：
  9
• 可旋转键数：
  2
• 环数：
  1.0
• sp3杂化的碳原子比例：
  1.0
• 拓扑面积：
  21.3
• 氢给体数：
  1
• 氢受体数：
  2

文献信息

• Novel Compounds
  申请人：Cheng Yun-Xing

  公开号：US20070259888A1

  公开（公告）日：2007-11-08

  Compounds of Formulae I, or pharmaceutically acceptable salts thereof: wherein X, R 1 , R 2 and R 3 are as defined in the specification as well as salts and pharmaceutical compositions including the compounds are prepared. They are useful in therapy, in particular in the management of pain.

  公式I的化合物，或其药用盐：其中X、R1、R2和R3如规范中定义的那样，以及包括这些化合物的盐和药物组合物已经准备好。它们在治疗中很有用，特别是在疼痛管理中。
• VLA-4 INHIBITORY DRUG
  申请人：Machinaga Nobuo

  公开号：US20090233901A1

  公开（公告）日：2009-09-17

  There is provided a VLA-4 inhibitory drug having good oral absorbability and exhibiting sufficient anti-inflammatory effects when administered orally. A compound represented by the following formula (I): wherein R 1 represents a hydrogen atom or a C1-8 alkyl group; R 2 represents a hydrogen atom, a halogen atom, a C1-8 alkoxy group, or a benzyloxy group which may be substituted; Q represents a monocyclic or bicyclic nitrogen-containing heterocyclic group which may be substituted, and has a nitrogen atom as the bonding site; Y represents an oxygen atom or CH 2 ; W represents a bicyclic aromatic hydrocarbon ring group which may be substituted, or a bicyclic aromatic heterocyclic group which may be substituted; R 3a , R 3b and R 3c each independently represent a hydrogen atom, a halogen atom, a C1-8 alkoxy group or a C1-8 alkyl group; and A 1 represents a nitrogen atom or C—R 3d (wherein R 3d represents a hydrogen atom, a halogen atom, a C1-8 alkoxy group or a C1-8 alkyl group), or a salt thereof, or a VLA-4 inhibitory drug comprising the compound or the salt as an active ingredient.

  提供了一种VLA-4抑制剂药物，具有良好的口服吸收性，并在口服给药时表现出足够的抗炎效果。其中，化合物的表示式如下（I）：其中，R1表示氢原子或C1-8烷基；R2表示氢原子、卤素原子、C1-8烷氧基或可取代的苄氧基；Q表示可取代的单环或双环含氮杂环基团，并具有氮原子作为键合位点；Y表示氧原子或CH2；W表示可取代的双环芳香烃环基团或可取代的双环芳香杂环基团；R3a、R3b和R3c分别独立地表示氢原子、卤素原子、C1-8烷氧基或C1-8烷基；A1表示氮原子或C-R3d（其中，R3d表示氢原子、卤素原子、C1-8烷氧基或C1-8烷基），或其盐，或包含该化合物或其盐作为活性成分的VLA-4抑制剂药物。
• US8129366B2
  申请人：——

  公开号：US8129366B2

  公开（公告）日：2012-03-06
• [EN] COMPOUNDS THAT ARE AGONISTS OF MUSCARINIC RECEPTORS AND THA MAY BE EFFECTIVE IN TREATING PAIN, ALZHEIMER'S DISEASE AND/OR SCHIZOPHRENIA<br/>[FR] COMPOSES AGONISTES DES RECEPTEURS MUSCARINIQUES QUI PEUVENT ETRE EFFICACES POUR TRAITER LA DOULEUR, LA MALADIE D'ALZHEIMER ET/OU LA SCHIZOPHRENIE
  申请人：ASTRAZENECA AB

  公开号：WO2007126362A1

  公开（公告）日：2007-11-08

  [EN] Compounds of Formulae I, or pharmaceutically acceptable salts thereof: [Chemical formula should be inserted here. Please see paper copy] I wherein X, R₁, R₂ and R₃ are as defined in the specification as well as salts and pharmaceutical compositions including the compounds are prepared. They are useful in therapy, in particular in the management of pain.
  [FR] La présente invention concerne des composés de formule (I) ou leurs sels pharmaceutiquement acceptables : [La formule chimique doit être insérée ici. Veuillez vous reporter à l'exemplaire papier] (I) dans laquelle X, R₁, R₂ et R₃ sont tels que définis dans le mémoire descriptif. L'invention concerne également des sels et des compositions pharmaceutiques qui incluent lesdits composés et qui ont une utilité thérapeutique, en particulier pour la gestion de la douleur.
• [EN] SUBSTITUTED BICYCLIC PIPERIDINE DERIVATIVES USEFUL AS T CELL ACTIVATORS<br/>[FR] DÉRIVÉS DE PIPÉRIDINE BICYCLIQUES SUBSTITUÉS UTILES EN TANT QU'ACTIVATEURS DE LYMPHOCYTES T
  申请人：BRISTOL MYERS SQUIBB CO

  公开号：WO2021133750A1

  公开（公告）日：2021-07-01

  Disclosed are compounds of Formula (I): or a salt thereof, wherein: X is CR6 or N; Y is CR3 or N; R1, R2, R3, R4, R5, R6, R7, and m are defined herein. Also disclosed are methods of using such compounds to inhibit the activity of one or both of diacylglycerol kinase alpha (DGKα) and diacylglycerol kinase zeta (DGKζ), and pharmaceutical compositions comprising such compounds. These compounds are useful in the treatment of viral infections and proliferative disorders, such as cancer.